ÂÜÀòÂÒÂ×

Nikki Martin has worked on healthcare issues advocacy for more than 16 years. She joined LUNGevity in 2018 to focus on accelerating access to precision medicine for lung cancer patients.

In this role, Nikki promotes the critical need for biomarker testing in lung cancer to ensure that the newly diagnosed and those at progression have the most information possible about their unique lung cancer in order to access the appropriate therapies or clinical trials.

Prior to joining LUNGevity, Nikki worked in Alliance & Advocacy Relations at Genentech, where she championed awareness of unmet needs and driving change in the patient community. She led advocacy outreach around next-generation sequencing and CMS' 14-day rule and expanding collaboration between CME providers and advocacy groups on provider and patient education on shared decision making.

Previous to Genentech, Nikki held two roles at Grifols/Novartis Diagnostics, first as associate director, global communications, and later as associate director, global public affairs. In those roles, she worked with global partners including sickle cell disease, hemophilia, and thalassemia patient advocacy groups, the Pan American Health Organization (PAHO), and the Asia Pacific Economic Cooperation (APEC) to educate the public, policy makers, and other stakeholders on improving transfusion safety. She started her career in Japan, where she worked at Cosmo PR managing AdvaMed (a medical device trade organization) public affairs activities in the Japanese market.

She earned her MA in International Trade Policy from the Middlebury Institute of International Studies, and a BS in Anthropology and BA in Spanish from Santa Clara University. Nikki lives in Davis, CA, with her wife and two dogs, Mia and Stuart.